GE HealthCare Technologies Inc.
GEHC
Kedudukan dalam Saham
#771
GE HealthCare Technologies Inc. is a global medical technology company that... GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Harga Saham
$69.86
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$31.56B
Perubahan (1 hari)
0.15%
Perubahan (1 tahun)
-8.19%
Negara
US
Perdagangan GE HealthCare Technologies Inc. (GEHC)
Kategori
Healthcare
Nisbah P/E bagi GE HealthCare Technologies Inc. (GEHC)
Nisbah P/E pada October 2026 TTM: 19.68
Menurut laporan kewangan dan harga saham terkini GE HealthCare Technologies Inc., nisbah P/E semasa (TTM) ialah 19.68. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 17.89.
Sejarah nisbah P/E bagi GE HealthCare Technologies Inc. dari 2019 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 19.68 | -11.73% |
| 2025 | 22.29 | 24.60% |
| 2024 | 17.89 | -20.27% |
| 2023 | 22.44 | 62.22% |
| 2022 | 13.83 | 13.91% |
| 2021 | 12.14 | 516.21% |
| 2020 | 1.97 | -88.99% |
| 2019 | 17.90 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 64.40 | 227.32% |
AU
|
|
| 44.30 | 125.16% |
US
|
|
| -47.78 | -342.82% |
US
|
|
| -123.90 | -729.71% |
US
|
|
| - | - |
US
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.